TY - JOUR
T1 - The Natural History of Inherited Retinal Dystrophy Due to Biallelic Mutations in the RPE65 Gene
AU - Chung, Daniel C.
AU - Bertelsen, Mette
AU - Lorenz, Birgit
AU - Pennesi, Mark E.
AU - Leroy, Bart P.
AU - Hamel, Christian P.
AU - Pierce, Eric
AU - Sallum, Juliana
AU - Larsen, Michael
AU - Stieger, Knut
AU - Preising, Markus
AU - Weleber, Richard
AU - Yang, Paul
AU - Place, Emily
AU - Liu, Emily
AU - Schaefer, Grace
AU - DiStefano-Pappas, Julie
AU - Elci, Okan U.
AU - McCague, Sarah
AU - Wellman, Jennifer A.
AU - High, Katherine A.
AU - Reape, Kathleen Z.
N1 - Funding Information:
Funding/Support: Funding support provided by Spark Therapeutics, Inc , Philadelphia, Pennsylvania, USA. Financial Disclosures: Daniel C. Chung and Katherine A. High are employees of and have equity/options in Spark Therapeutics, Inc, and have a patent pending pertaining to the primary endpoint measure licensed to Spark Therapeutics, Inc. Mark E. Pennesi is a consultant for Spark Therapeutics, Inc; reports grants from Foundation Fighting Blindness Career Development Award (CD-NMT-0714-0648); and receives unrestricted departmental funding from Research to Prevent Blindness and grants from NIH ( P30EY010572 ) and Foundation Fighting Blindness (C-CL-0711-0534-OHSU01) through his employer, Casey Eye Institute. Emily Liu, Grace Schaefer, and Kathleen Z. Reape are employees of and have equity/options in Spark Therapeutics, Inc. Birgit Lorenz and Markus Preising report grants from the German Research Council DFG LO457/3 and LO457/5. Paul Yang reports grants from NIH ( K08EY026650 and P30EY010572 ) and Foundation Fighting Blindness Career Development Award (CD-NMT-0714-0648); receives unrestricted departmental funding from Research to Prevent Blindness through his employer, Casey Eye Institute; is a consultant for Astellas; and receives clinical trial support from Sanofi, AGTC, and NST. Julie DiStefano-Pappas and Okan U. Elci are employees of Westat, Rockville, Maryland, USA, which was contracted by Spark Therapeutics, Inc for this study. Sarah McCague is a clinical coordinator of a study sponsored by Spark Therapeutics, Inc; receives salary support from Spark Therapeutics, Inc and the Center for Cellular and Molecular Therapeutics (CCMT) at The Children's Hospital of Philadelphia; and has a patent pending licensed to Spark Therapeutics, Inc. Jennifer A. Wellman is a former employee of and has a patent pending pertaining to the primary endpoint measure licensed to Spark Therapeutics, Inc. The following authors have no financial disclosures: Mette Bertelsen, Bart P. Leroy, Christian P. Hamel, Eric Pierce, Juliana Sallum, Michael Larsen, Knut Stieger, Richard Weleber, and Emily Place. All authors attest that they meet the current ICMJE criteria for authorship.
Funding Information:
Funding/Support: Funding support provided by Spark Therapeutics, Inc, Philadelphia, Pennsylvania, USA. Financial Disclosures: Daniel C. Chung and Katherine A. High are employees of and have equity/options in Spark Therapeutics, Inc, and have a patent pending pertaining to the primary endpoint measure licensed to Spark Therapeutics, Inc. Mark E. Pennesi is a consultant for Spark Therapeutics, Inc; reports grants from Foundation Fighting Blindness Career Development Award (CD-NMT-0714-0648); and receives unrestricted departmental funding from Research to Prevent Blindness and grants from NIH (P30EY010572) and Foundation Fighting Blindness (C-CL-0711-0534-OHSU01) through his employer, Casey Eye Institute. Emily Liu, Grace Schaefer, and Kathleen Z. Reape are employees of and have equity/options in Spark Therapeutics, Inc. Birgit Lorenz and Markus Preising report grants from the German Research Council DFG LO457/3 and LO457/5. Paul Yang reports grants from NIH (K08EY026650 and P30EY010572) and Foundation Fighting Blindness Career Development Award (CD-NMT-0714-0648); receives unrestricted departmental funding from Research to Prevent Blindness through his employer, Casey Eye Institute; is a consultant for Astellas; and receives clinical trial support from Sanofi, AGTC, and NST. Julie DiStefano-Pappas and Okan U. Elci are employees of Westat, Rockville, Maryland, USA, which was contracted by Spark Therapeutics, Inc for this study. Sarah McCague is a clinical coordinator of a study sponsored by Spark Therapeutics, Inc; receives salary support from Spark Therapeutics, Inc and the Center for Cellular and Molecular Therapeutics (CCMT) at The Children's Hospital of Philadelphia; and has a patent pending licensed to Spark Therapeutics, Inc. Jennifer A. Wellman is a former employee of and has a patent pending pertaining to the primary endpoint measure licensed to Spark Therapeutics, Inc. The following authors have no financial disclosures: Mette Bertelsen, Bart P. Leroy, Christian P. Hamel, Eric Pierce, Juliana Sallum, Michael Larsen, Knut Stieger, Richard Weleber, and Emily Place. All authors attest that they meet the current ICMJE criteria for authorship.Other Acknowledgments: Medical writing support was provided by Christina Ohnsman, of CMO Medical Communications, and Lisa Feder, PhD, of Peloton Advantage, Parsippany, New Jersey, USA, and was funded by Spark Therapeutics, Inc. Assistance in data organization was provided by W. Christopher Whitebirch of the Ophthalmic Genetics Division, Casey Eye Institute, Oregon Health & Science University, Portland, Oregon, USA. Genetic mutation nomenclature support was provided by Karmen Trzupek, MS, CGC, InformedDNA, St. Petersburg, Florida, USA.
Publisher Copyright:
© 2018
PY - 2019/3
Y1 - 2019/3
N2 - Purpose: To delineate the natural history of visual parameters over time in individuals with biallelic RPE65 mutation–associated inherited retinal dystrophy (IRD); describe the range of causative mutations; determine potential genotype/phenotype relationships; and describe the variety of clinical diagnoses. Design: Global, multicenter, retrospective chart review. Methods: STUDY POPULATION: Seventy individuals with biallelic RPE65 mutation–associated IRD. PROCEDURES: Data were extracted from patient charts. MEASUREMENTS: Visual acuity (VA), Goldmann visual field (GVF), optical coherence tomography, color vision testing, light sensitivity testing, and electroretinograms (retinal imaging and fundus photography were collected and analyzed when available). Results: VA decreased with age in a nonlinear, positive-acceleration relationship (P <.001). GVF decreased with age (P <.0001 for both V4e and III4e), with faster GVF decrease for III4e stimulus vs V4e (P =.0114, left eye; P =.0076, right eye). On average, a 1-year increase in age decreased III4e GVF by ∼25 sum total degrees in each eye while V4e GVF decreased by ∼37 sum total degrees in each eye, although individual variability was observed. A total of 78 clinical diagnoses and 56 unique RPE65 mutations were recorded, without discernible RPE65 mutation genotype/phenotype relationships. Conclusions: The number of clinical diagnoses and lack of a consistent RPE65 mutation–to–phenotype correlation underscore the need for genetic testing. Significant relationships between age and worsening VA and GVF highlight the progressive loss of functional retina over time. These data may have implications for optimal timing of treatment for IRD attributable to biallelic RPE65 mutations.
AB - Purpose: To delineate the natural history of visual parameters over time in individuals with biallelic RPE65 mutation–associated inherited retinal dystrophy (IRD); describe the range of causative mutations; determine potential genotype/phenotype relationships; and describe the variety of clinical diagnoses. Design: Global, multicenter, retrospective chart review. Methods: STUDY POPULATION: Seventy individuals with biallelic RPE65 mutation–associated IRD. PROCEDURES: Data were extracted from patient charts. MEASUREMENTS: Visual acuity (VA), Goldmann visual field (GVF), optical coherence tomography, color vision testing, light sensitivity testing, and electroretinograms (retinal imaging and fundus photography were collected and analyzed when available). Results: VA decreased with age in a nonlinear, positive-acceleration relationship (P <.001). GVF decreased with age (P <.0001 for both V4e and III4e), with faster GVF decrease for III4e stimulus vs V4e (P =.0114, left eye; P =.0076, right eye). On average, a 1-year increase in age decreased III4e GVF by ∼25 sum total degrees in each eye while V4e GVF decreased by ∼37 sum total degrees in each eye, although individual variability was observed. A total of 78 clinical diagnoses and 56 unique RPE65 mutations were recorded, without discernible RPE65 mutation genotype/phenotype relationships. Conclusions: The number of clinical diagnoses and lack of a consistent RPE65 mutation–to–phenotype correlation underscore the need for genetic testing. Significant relationships between age and worsening VA and GVF highlight the progressive loss of functional retina over time. These data may have implications for optimal timing of treatment for IRD attributable to biallelic RPE65 mutations.
UR - http://www.scopus.com/inward/record.url?scp=85059158998&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059158998&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2018.09.024
DO - 10.1016/j.ajo.2018.09.024
M3 - Article
C2 - 30268864
AN - SCOPUS:85059158998
SN - 0002-9394
VL - 199
SP - 58
EP - 70
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
ER -